Cargando…

Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review

BACKGROUND: Despite the fact that nephron-sparing treatment is considered preferable from a surgical perspective patients’ quality of life (QoL) following different types of nephron-sparing treatments remains unclear. PURPOSE: To investigate the quality of life and complications after nephron-sparin...

Descripción completa

Detalles Bibliográficos
Autores principales: Junker, Theresa, Duus, Louise, Rasmussen, Benjamin S. B., Azawi, Nessn, Lund, Lars, Graumann, Ole, Nørgaard, Birgitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725354/
https://www.ncbi.nlm.nih.gov/pubmed/34983648
http://dx.doi.org/10.1186/s13643-021-01868-2
_version_ 1784626098695307264
author Junker, Theresa
Duus, Louise
Rasmussen, Benjamin S. B.
Azawi, Nessn
Lund, Lars
Graumann, Ole
Nørgaard, Birgitte
author_facet Junker, Theresa
Duus, Louise
Rasmussen, Benjamin S. B.
Azawi, Nessn
Lund, Lars
Graumann, Ole
Nørgaard, Birgitte
author_sort Junker, Theresa
collection PubMed
description BACKGROUND: Despite the fact that nephron-sparing treatment is considered preferable from a surgical perspective patients’ quality of life (QoL) following different types of nephron-sparing treatments remains unclear. PURPOSE: To investigate the quality of life and complications after nephron-sparing treatment of renal cell carcinomas of stage T1. MATERIALS AND METHODS: A systematic search of six databases was carried out. We included studies that reported the quality of life and complications in patients aged 18 years or older following nephron-sparing treatment of renal cell carcinoma stage T1. The quality assessment was performed using the Critical Appraisal Skills Programme (CASP) checklist for cohort studies and the CASP Randomized Controlled Trial Checklist. Data were analyzed using a narrative approach. RESULTS: Eight studies were included, six of which investigated QoL after partial nephrectomy and two after ablation therapies. Seven studies reported complications. Three studies reported higher QoL scores after partial nephrectomy compared to radical nephrectomy. Two studies showed that QoL increased or returned to baseline levels up to 12 months following partial nephrectomy. One study reported a gradual increase in QoL after radiofrequency ablation, and one study reported that all patients recovered to baseline QoL following cryoablation. Across studies, we found a complication rate up to 20% after partial nephrectomy and up to 12.5% after ablation therapy. CONCLUSIONS: The results of this systematic review suggest that nephron-sparing treatment appears to be superior or comparable to other treatment alternatives with regard to QoL outcomes. Additionally, based on the studies included in this review, partial nephrectomy appears to have a higher complication rate compared with ablation therapies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020155594 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-021-01868-2.
format Online
Article
Text
id pubmed-8725354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87253542022-01-06 Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review Junker, Theresa Duus, Louise Rasmussen, Benjamin S. B. Azawi, Nessn Lund, Lars Graumann, Ole Nørgaard, Birgitte Syst Rev Research BACKGROUND: Despite the fact that nephron-sparing treatment is considered preferable from a surgical perspective patients’ quality of life (QoL) following different types of nephron-sparing treatments remains unclear. PURPOSE: To investigate the quality of life and complications after nephron-sparing treatment of renal cell carcinomas of stage T1. MATERIALS AND METHODS: A systematic search of six databases was carried out. We included studies that reported the quality of life and complications in patients aged 18 years or older following nephron-sparing treatment of renal cell carcinoma stage T1. The quality assessment was performed using the Critical Appraisal Skills Programme (CASP) checklist for cohort studies and the CASP Randomized Controlled Trial Checklist. Data were analyzed using a narrative approach. RESULTS: Eight studies were included, six of which investigated QoL after partial nephrectomy and two after ablation therapies. Seven studies reported complications. Three studies reported higher QoL scores after partial nephrectomy compared to radical nephrectomy. Two studies showed that QoL increased or returned to baseline levels up to 12 months following partial nephrectomy. One study reported a gradual increase in QoL after radiofrequency ablation, and one study reported that all patients recovered to baseline QoL following cryoablation. Across studies, we found a complication rate up to 20% after partial nephrectomy and up to 12.5% after ablation therapy. CONCLUSIONS: The results of this systematic review suggest that nephron-sparing treatment appears to be superior or comparable to other treatment alternatives with regard to QoL outcomes. Additionally, based on the studies included in this review, partial nephrectomy appears to have a higher complication rate compared with ablation therapies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020155594 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-021-01868-2. BioMed Central 2022-01-04 /pmc/articles/PMC8725354/ /pubmed/34983648 http://dx.doi.org/10.1186/s13643-021-01868-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Junker, Theresa
Duus, Louise
Rasmussen, Benjamin S. B.
Azawi, Nessn
Lund, Lars
Graumann, Ole
Nørgaard, Birgitte
Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review
title Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review
title_full Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review
title_fullStr Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review
title_full_unstemmed Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review
title_short Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review
title_sort quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage t1—a systematic review
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725354/
https://www.ncbi.nlm.nih.gov/pubmed/34983648
http://dx.doi.org/10.1186/s13643-021-01868-2
work_keys_str_mv AT junkertheresa qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview
AT duuslouise qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview
AT rasmussenbenjaminsb qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview
AT azawinessn qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview
AT lundlars qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview
AT graumannole qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview
AT nørgaardbirgitte qualityoflifeandcomplicationsafternephronsparingtreatmentofrenalcellcarcinomastaget1asystematicreview